


REMARKS

The Examiner has requested a restriction/election with respect to the above-identified application. Specifically, the Examiner states that the multiple methods for treating a host for rheumatoid arthritis comprising a dose of acceptable PAD inhibitors are separate and distinct inventions. The Examiner requests an election of one species for prosecution on the merits.

Applicant agrees that Claim 1 is generic. Applicant believes that Claims 1-6 are interrelated to one another and should be prosecuted as part of the same patent application. However, in order to fully respond to the Office Action, Applicant elects the species disclosed in Claim 4, i.e. the species wherein the PAD inhibitor has a side chain including a benzamide group to the left and an ester group to the right of a peptide bond. An "R" group has also been added to the PAD inhibitor shown in new Figure 1.

If there are any fees incurred by this Amendment Letter, please deduct them from our Deposit Account No. 23-0830.

Respectfully submitted,



Veronica-Adele R. Cao
Reg. No. 52,694
Tel: (480) 994-8888
Attorney for Applicant

Weiss, Moy & Harris, P.C.
4204 N. Brown Ave.
Scottsdale, AZ 85251